SCHEMBL3767957

SCHEMBL3767957

O=C(O)c1ccc(-c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 8/20 0.81
CAMKK2 Q96RR4 6/20 0.81
SGK1 O00141 3/20 0.81
MAP4K4 O95819 2/20 0.61
PRKD3 O94806 1/20 0.61
EGFR P00533 1/20 0.61
NTRK1 P04629 1/20 0.61
LCK P06239 1/20 0.61
FYN P06241 1/20 0.61
FLT4 P35916 1/20 0.61
KDR P35968 1/20 0.61
FLT3 P36888 1/20 0.61
FRK P42685 1/20 0.61
CLK2 P49760 1/20 0.61
MAP4K2 Q12851 1/20 0.61
CAMK2B Q13554 1/20 0.61
CAMK2G Q13555 1/20 0.61
CAMK2D Q13557 1/20 0.61
PTK6 Q13882 1/20 0.61
NTRK3 Q16288 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768633 0.94 AXL (0.92) AXLCAMKK2SGK1PRKD3EGFR
SCHEMBL3774587 0.90 AXL (1.00) AXLCAMKK2SGK1PRKD3EGFR
SCHEMBL8940901 0.88 AXL (0.70) AXLCAMKK2SGK1MAP4K4PRKD3
SCHEMBL3759528 0.88 AXL (0.81) AXLCAMKK2SGK1PRKD3EGFR
SCHEMBL8320085 0.84 AXL (0.76) AXLCAMKK2SGK1CLK1DYRK1A
SCHEMBL3765574 0.84 MAP3K11 (0.82) AXLCAMKK2SGK1PRKD3EGFR
SCHEMBL3763777 0.84 AXL (0.76) AXLCAMKK2SGK1PRKD3EGFR
SCHEMBL21069147 0.83 AXL (0.60) AXLCAMKK2SGK1EGFRKDR
SCHEMBL3764743 0.82 AXL (0.69) AXLCAMKK2SGK1MAP4K4PRKD3
SCHEMBL3760212 0.82 AXL (0.80) AXLCAMKK2SGK1PRKD3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US claimed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US claimed
WO-2021006707-A1 USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES 한양대학교 산학협력단 2021-01-14 WO disclosed
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US disclosed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO disclosed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes SGK1, SGK2, SGK3 AXL 1542/4885CAMKK2 157/4885SGK1 1/4885
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines SGK1, SGK2, SGK3 AXL 1432/4885CAMKK2 125/4885SGK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.